Objective:To explore the clinical efficacy of immediately adding mifepristone tablets after medical abortion in improving the complete abortion rate.Methods:This study was a randomized controlled trial. A total of 300 patients with medical abortion in Family Planning Center of Hangzhou Women's Hospital from January 2022 to December 2023 were randomly divided into high-dose group, low-dose group and control group by the digital table method, with 100 cases in each group. The low-dose group was given mifepristone tablets 25 mg bid×5 d immediately after medical abortion; the high-dose group was given mifepristone tablets 50 mg bid×5 d immediately after medical abortion; the control did not use mifepristone after medical abortion. The complete abortion rate, the duration of vaginal bleeding, the amount of vaginal bleeding and the incidence of adverse events such as complications were compared among the three groups.Results:For the three indicators of complete abortion rate, duration of vaginal bleeding and the proportion of vaginal bleeding volume exceeding the individual's customary menstrual flow, they were 92.0% (92/100), (9.0±2.8) d and 0% respectively in the low-dose group, 89.0% (89/100), (10.8±3.0) d and 0% respectively in the high-dose group, and 67.0% (67/100), (16.5±2.6) d and 11.0% (11/100) respectively in the control. The complete abortion rate in the high-dose group and low-dose group was significantly higher than that in the control (all P<0.001), while the duration and the proportion of vaginal bleeding volume exceeding the individual's customary menstrual flow were significantly lower than those in the control (all P<0.001), and the differences were statistically significant. The incidence of complications and the occurrence level of other adverse events were similar between the high-dose and low-dose groups and the control, and the differences were not statistically significant (all P>0.05). Conclusion:Immediately giving mifepristone tablets after medical abortion can effectively improve the complete abortion rate, significantly reduce the amount and duration of vaginal bleeding in patients, and the security of the medication is good.

Objective:To explore the clinical efficacy of immediately adding mifepristone tablets after medical abortion in improving the complete abortion rate.Methods:This study was a randomized controlled trial. A total of 300 patients with medical abortion in Family Planning Center of Hangzhou Women's Hospital from January 2022 to December 2023 were randomly divided into high-dose group, low-dose group and control group by the digital table method, with 100 cases in each group. The low-dose group was given mifepristone tablets 25 mg bid×5 d immediately after medical abortion; the high-dose group was given mifepristone tablets 50 mg bid×5 d immediately after medical abortion; the control did not use mifepristone after medical abortion. The complete abortion rate, the duration of vaginal bleeding, the amount of vaginal bleeding and the incidence of adverse events such as complications were compared among the three groups.Results:For the three indicators of complete abortion rate, duration of vaginal bleeding and the proportion of vaginal bleeding volume exceeding the individual's customary menstrual flow, they were 92.0% (92/100), (9.0±2.8) d and 0% respectively in the low-dose group, 89.0% (89/100), (10.8±3.0) d and 0% respectively in the high-dose group, and 67.0% (67/100), (16.5±2.6) d and 11.0% (11/100) respectively in the control. The complete abortion rate in the high-dose group and low-dose group was significantly higher than that in the control (all P<0.001), while the duration and the proportion of vaginal bleeding volume exceeding the individual's customary menstrual flow were significantly lower than those in the control (all P<0.001), and the differences were statistically significant. The incidence of complications and the occurrence level of other adverse events were similar between the high-dose and low-dose groups and the control, and the differences were not statistically significant (all P>0.05). Conclusion:Immediately giving mifepristone tablets after medical abortion can effectively improve the complete abortion rate, significantly reduce the amount and duration of vaginal bleeding in patients, and the security of the medication is good.

OBJECTIVE: To investigate the relationship between 22q11.2 duplication and clinical phenotype. METHODS: Eight fetuses with 22q11.2 duplication syndrome diagnosed by chromosome microarray analysis (CMA) through amniocentesis from February 2015 to March 2017 were enrolled in the study. The prenatal diagnostic indications, fetal ultrasound, chromosome karyotype, peripheral blood CMA results of parents, pregnancy outcomes and follow-up of postnatal growth and development were retrospectively analyzed. RESULTS: Prenatal serological screening indicated 6 cases with high risk of trisomy 21, 1 case with nuchal fold (NF) thickening and 1 case of maternal chromosomal balanced translocation. Fetal ultrasonography showed 1 case of NF thickening, 1 case of fetal cerebral ventriculomegaly and 6 cases with normal ultrasound. CMA demonstrated that the size of duplication was between 651 kb and 3.26 Mb, and 22q11.2 duplication. Parents' CMA results revealed that 6 cases inherited from one of the parents with normal phenotype, and the parents of 2 cases refused the CMA test. Two couples chose induced labor; 6 cases of continued pregnancy had normal phenotypes at birth. All 6 cases were followed up with longest of 3.5 years. The growth and psychological development were normal in 5 cases, and one case was growth retardation. CONCLUSIONS There were no specific clinical phenotypes in 22q11.2 duplication syndrome, and most of them were inherited from one parent who has normal phenotype.
Abnormalities, Multiple ; diagnosis ; genetics ; Chromosome Duplication ; genetics ; Chromosomes, Human, Pair 22 ; genetics ; DiGeorge Syndrome ; diagnosis ; genetics ; Female ; Humans ; Male ; Pregnancy ; Pregnancy Outcome ; Prenatal Diagnosis ; Retrospective Studies